Please join PharmaMar for a Research & Development Day in New York City on April 24th.
Management to discuss scientific pipeline including Phase 3 pivotal study with Lurbinectedin (PM1183) for platinum-resistant ovarian cancer.
Expert Guest Speakers to Include:
Melina Telli, MD
Stanford School of Medicine, Stanford, CA
Dr Martin Forster, MBBS MRCP PhD
UCL Cancer Institute
University College Hospital, London, UK
Sue Friedman, DVM
Facing Our Risks of Cancer Empowered (FORCE)
For more information or to RSVP please contact Patrick Till (email@example.com)